Premium
Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas
Author(s) -
Yang Qifeng,
Sakurai Takeo,
Mori Ichiro,
Yoshimura Goro,
Nakamura Misa,
Nakamura Yasushi,
Suzuma Takaomi,
Tamaki Takeshi,
Umemura Teiji,
Kakudo Kennichi
Publication year - 2001
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(20010701)92:1<54::aid-cncr1291>3.0.co;2-8
Subject(s) - medicine , oncology , immunohistochemistry , breast cancer , proportional hazards model , breast carcinoma , carcinoma , lymph node , adjuvant therapy , cohort , cancer , pathology
BACKGROUND BRCA1 is a tumor suppressor gene that is responsible for hereditary breast and ovarian carcinoma syndrome. The primary objective of the current study was to investigate the influence of BRCA1 expression on the prognoses of sporadic breast carcinomas. METHODS A cohort of 175 Japanese women with invasive breast carcinoma who had no family history in first‐degree relatives was studied. Expression of BRCA1 was determined by an immunohistochemical procedure in which the MS110 monoclonal antibody was used. Kaplan–Meier and Cox proportional regression survival analyses were used to compare negative and positive BRCA1 patients. RESULTS One hundred fifteen (65.7%) of the 175 specimens showed positive BRCA1 staining (> 10% cells were immunoreactive). During a median follow‐up of 4.4 years, negative BRCA1 patients had worse disease free survival than positive BRCA1 patients (35 % vs. 7%, respectively; P < 0.0001). BRCA1 expression was significantly inversely correlated with histologic grade ( P < 0.0001) but not with lymph node status or other conventional prognostic markers. In multivariate analysis using the Cox regression model, positive BRCA1 emerged as an independent prognostic indicator for disease free survival. CONCLUSIONS The results of this study suggest that BRCA1 may be a valuable marker for identifying women with sporadic breast carcinoma at high risk of developing recurrence, and who may be candidates for trials investigating new therapies in combination with standard adjuvant therapy. Cancer 2001;92:54–60. © 2001 American Cancer Society.